Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Fat intake and obesity are positively correlated with pancreatic cancer in humans. N-nitrosobis(2-oxopropyl)amine (BOP) induces pancreatic ductal adenocarcinomas limited to Syrian golden hamsters, other rodents not being susceptible. In the present study, we found markedly high levels of serum triglycerides (TGs) and total cholesterol (TC) in Syrian golden hamsters, but not C57BL/6 mice, ICR mice, F344 rats and Wistar rats. Consistent with this, lipoprotein lipase (LPL) activities in the liver were lower in hamsters compared with mice and rats. To examine effects of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, on LPL expression, serum lipid levels and pancreatic cancer development, 6-week-old female Syrian golden hamsters were subcutaneously injected with BOP (10 mg/kg body wt) four times in a week and thereafter fed a diet containing 800 p.p.m. pioglitazone for 22 weeks. The treatment elevated LPL mRNA expression in the liver and significantly improved hyperlipidemia with serum levels of TG and TC being decreased to 62 and 71%, respectively, of the control values. Concurrently, the incidence and multiplicity of pancreatic ductal adenocarcinomas were significantly decreased by pioglitazone in comparison with the controls (38 versus 80%, P < 0.01 and 0.55 +/- 0.15 versus 1.37 +/- 0.22, P < 0.01, respectively). The suppression rates were greater in invasive adenocarcinomas than non-invasive ones. The incidence of cholangiocellular carcinomas was also reduced. Thus, suppression of pancreatic adenocarcinoma development by pioglitazone is possibly associated with improvement in the serum lipid profile, and hyperlipidemia could be an enhancing factor for development of pancreatic cancer in hamsters.
Takeuchi
Yoshito
Y
Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
Takahashi
Mami
M
Sakano
Katsuhisa
K
Mutoh
Michihiro
M
Niho
Naoko
N
Yamamoto
Masafumi
M
Sato
Hidetaka
H
Sugimura
Takashi
T
Wakabayashi
Keiji
K
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D002273:Carcinogens; D006224:Cricetinae; D005260:Female; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D008024:Ligands; D008071:Lipoprotein Lipase / Q000378:metabolism; D008647:Mesocricetus; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D009602:Nitrosamines; D047495:PPAR gamma / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D000077205:Pioglitazone; D051381:Rats; D011916:Rats, Inbred F344; D017208:Rats, Wistar; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002273:Carcinogens; D008024:Ligands; D009602:Nitrosamines; D047495:PPAR gamma; D045162:Thiazolidinediones; C013622:nitrosobis(2-oxopropyl)amine; D008071:Lipoprotein Lipase; D000077205:Pioglitazone